BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35890254)

  • 21. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components.
    Lin TJ; Lin HT; Chang WT; Mitapalli S P; Hsiao PW; Yin SY; Yang NS
    Mol Cancer; 2015 Sep; 14():174. PubMed ID: 26403780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
    Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
    Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells: activation and maturation--applications for cancer immunotherapy.
    Sheng KC; Pietersz GA; Wright MD; Apostolopoulos V
    Curr Med Chem; 2005; 12(15):1783-800. PubMed ID: 16029147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
    Sheen MR; Fiering S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy.
    Kohnepoushi C; Nejati V; Delirezh N; Biparva P
    Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.
    Vandenberk L; Garg AD; Verschuere T; Koks C; Belmans J; Beullens M; Agostinis P; De Vleeschouwer S; Van Gool SW
    Oncoimmunology; 2016 Feb; 5(2):e1083669. PubMed ID: 27057467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity.
    Eko FO; Mania-Pramanik J; Pais R; Pan Q; Okenu DM; Johnson A; Ibegbu C; He C; He Q; Russell R; Black CM; Igietseme JU
    BMC Immunol; 2014 Dec; 15():584. PubMed ID: 25551828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
    Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
    J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
    Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
    Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
    Altin JG; van Broekhoven CL; Parish CR
    Expert Opin Biol Ther; 2004 Nov; 4(11):1735-47. PubMed ID: 15500402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating dendritic cells as an in vitro screening tool for immunotherapeutic formulations.
    El-Murr T; Patel A; Sedlak C; D'Souza-Lobo B
    J Immunol Methods; 2018 Aug; 459():55-62. PubMed ID: 29800576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
    Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.